Multicenter retrospective evaluation of treatment for high-risk Acute Promyelocytic Leukemia (APL)

• Total number of HERO sites: 7

• Status: In-process; Abstract presented at 2023 American Society of Hematology Annual Meeting

• Click to see abstract